Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 455-482

  Montecucco, Fabrizio ^a,b   Favari, Elda ^c   Norata, Giuseppe Danilo ^d,e,f   Ronda, Nicoletta ^c   Nofer, Jerzy Roch ^g   Vuilleumier, Nicolas ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Department of Human Protein Science ^*  (Switzerland)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Ospedale Bassini   (Italy)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

ApoA I; Autoimmune disease; HDL; Innate immunity; Systemic inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; ATRELEUTON; AUTOANTIBODY; CD14 ANTIGEN; CD40 ANTIGEN; CELECOXIB; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL ESTER; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUPROFEN; INFLIXIMAB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; BIOLOGICAL MARKER; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTERIAL WALL THICKNESS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CONFERENCE PAPER; CROHN DISEASE; HUMAN; IMMUNOLOGICAL SYNAPSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LIPID RAFT; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; ULCERATIVE COLITIS; VASCULITIS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL MEMBRANE; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOLIPOPROTEIN A-I; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIPOPROTEINS, HDL; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MEMBRANE MICRODOMAINS; PROTEIN CONFORMATION; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84919683070     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_14     Document Type: Conference Paper

References (166)

1. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12:178-180.
2. Akgun S, Ertel NH, Mosenthal A, Oser W (1998) Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 131:103-108.
3. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, Norata GD (2010) Circulating CD4+CD25hiCD127lo regulatory t-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 30:1832-1841.
4. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini AG, Norata GD (2012a) Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc 1:27-41.
5. Ammirati E, Monaco C, Norata GD (2012b) Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T-cells during atherosclerosis. Circ Res 111:e48-e49.
6. Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H, Ebrahimi A, Tavilani H, Pourmotabbed T (2012) Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol 167:1279-1286.
7. Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B (1997) Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Proc Natl Acad Sci USA 94:8622-8627.
8. Bacchetta R, Gambineri E, Roncarolo MG (2007) Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 120:227-235.
9. Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM (2013) Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol 168:984-989.
10. Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4:675-687.
11. Batuca JR, Ames PR, Isenberg DA, Alves JD (2007) Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 1108:137-146.
12. Beck WH, Adams CP, Biglang-Awa IM, Patel AB, Vincent H, Haas-Stapleton EJ, Weers PM (2013) Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties. Biochim Biophys Acta 1828:1503-1510.
13. Bilate AM, Lafaille JJ (2010) Can TNF-alpha boost regulatory T cells? J Clin Invest 120:4190-4192.
14. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, Huizinga TW, van de Stadt RJ, Dijkmans BA, van der Linden S (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62:842-845.
15. Borba EF, Carvalho JF, Bonfa E (2006) Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 13:203-208.
16. Buffinton GD, Doe WF (1995) Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med 19:911-918.
17. Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST (1997) Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 42:651-655.
18. Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F (2013) Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb Haemost 109:854-868.
19. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835-2838.
20. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60:2870-2879.
21. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST (2012) Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71:1157-1162.
22. Cheng AM, Handa P, Tateya S, Schwartz J, Tang C, Mitra P, Oram JF, Chait A, Kim F (2012) Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS ONE 7:e33917.
23. Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK (2004) Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 43:120-124.
24. Cheung YF, O K, Tam SC, Siow YL (2005) Induction of MCP1, CCR2, and iNOS expression in THP-1 macrophages by serum of children late after Kawasaki disease. Pediatr Res 58:1306-1310.
25. Cheung YF, Wong SJ, Ho MH (2007) Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki disease. Arch Dis Child 92:43-47.
26. Chi H (2011) Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 32:16-24.
27. Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC, Chou P (1997) Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 260:15-26.
28. Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, Shalev V (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7: e1000336.
29. Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460-469.
30. Cimen F, Yildirmak ST, Ergen A, Cakmak M, Dogan S, Yenice N, Sezgin F (2012) Serum lipid, lipoprotein and oxidatively modified low density lipoprotein levels in active or inactive patients with Behcet’s disease. Indian J Dermatol 57:97-101.
31. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415.
32. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Stahle M, Nestle FO, Girolomoni G, Krueger JG (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785-1796.
33. Davidson MH (2012) HDL and CETP inhibition: will this DEFINE the future? Curr Treat Options Cardiovasc Med 14:384-390
34. de Carvalho JF, Bonfá E, Borba EF (2008) Systemic lupus erythematosus and “lupus dyslipoproteinemia”. Autoimmun Rev 7:246-250.
35. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Röcken M, Lütjohann D, Wright SD, Schultze JL, Latz E (2014) High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 15:152-160.
36. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, Dillon MJ, Deanfield JE (1996) Endothelial dysfunction late after Kawasaki disease. Circulation 94:2103-2106.
37. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993-2000.
38. Dolinsky VW, Douglas DN, Lehner R, Vance DE (2004) Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 378:967-974.
39. Eckel RH (1989) Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060-1068.
40. Ehrenstein MR, Jury EC, Mauri C (2005) Statins for atherosclerosis-as good as it gets? N Engl J Med 352:73-75.
41. El Harchaoui K, Arsenault BJ, Franssen R, Despres JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM (2009) High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 150:84-93.
42. Eritsland J, Arnesen H, Smith P, Seljeflot I, Dahl K (1989) Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile. J Oslo City Hosp 39:97-101.
43. Ettinger WH, Klinefelter HF, Kwiterovitch PO (1987) Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 63:167-172.
44. Ewart HS, Carroll R, Severson DL (1997) Lipoprotein lipase activity in rat cardiomyocytes is stimulated by insulin and dexamethasone. Biochem J 327:439-442.
45. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497.
46. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527-2533.
47. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48:11067-11074.
48. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA (2005) Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 52:3955-3965.
49. Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, Ripley B, Serada S, Nishikawa T, Kimura A, Nomura S, Kishimoto T, Naka T (2011) The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 186:32-40.
50. García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X (2008) High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 38:686-692.
51. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-1741.
52. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD (2006) Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 8:R82.
53. Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, Drosos AA (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38:13-19.
54. Gordon SM, Davidson WS (2012) Apolipoprotein A-I mimetics and high-density lipoprotein function. Curr Opin Endocrinol Diabetes Obes 19:109-114.
55. Graler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551-553.
56. Grand RJ, Ramakrishna J, Calenda KA (1995) Inflammatory bowel disease in the pediatric patient. Gastroenterol Clin North Am 24:613-632.
57. Grinberg-Bleyer Y, Saadoun D, Baeyens A, Billiard F, Goldstein JD, Grégoire S, Martin GH, Elhage R, Derian N, Carpentier W, Marodon G, Klatzmann D, Piaggio E, Salomon BL (2010) Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 120:4558-4568.
58. Gruaz L, Delucinge-Vivier C, Descombes P, Dayer JM, Burger D (2010) Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes. PLoS ONE 5:e9418.
59. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR (1999) Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 40:245-252.
60. Gu X, Lawrence R, Krieger M (2000) Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection. J Biol Chem 275:9120-9130.
61. Gupta N, DeFranco AL (2007) Lipid rafts and B cell signaling. Semin Cell Dev Biol 18:616-626.
62. Haas MJ, Mooradian AD (2011) Inflammation, high-density lipoprotein and cardiovascular dysfunction. Curr Opin Infect Dis 24:265-272.
63. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt RLCAT (2012) HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 97:E248-E256.
64. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M (2008) Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 10:213.
65. Hargrove GM, Junco A, Wong NC (1999) Hormonal regulation of apolipoprotein AI. J Mol Endocrinol 22:103-111.
66. Hassan HH, Denis M, Krimbou L, Marcil M, Genest J (2006) Cellular cholesterol homeostasis in vascular endothelial cells. Can J Cardiol 22:35B-40B
67. Heinecke JW (2009) The HDL, proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 50(Suppl):S167-S171.
68. Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53:1618-1624.
69. Hua X, Su J, Svenungsson E, Hurt-Camejo E, Jensen-Urstad K, Angelin B, Båvenholm P, Frostegård J (2009) Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 38:184-189.
70. Jafarnejad A, Bathaie SZ, Nakhjavani M, Hassan MZ (2008) Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. J Pharmacol Exp Ther 324:850-857.
71. Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT (2013) High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol 40:825-830.
72. Jiao YL, Wu MP (2008) Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43:83-87.
73. Juárez-Rojas J, Medina-Urrutia A, Posadas-Sánchez R, Jorge-Galarza E, Mendoza-Pérez E, Caracas-Portilla N, Cardoso-Saldaña G, Muñoz-Gallegos G, Posadas-Romero C (2008) High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus 17:981-987.
74. Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177:7416-7422.
75. Kabouridis PS, Jury EC (2008) Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett 582:3711-3718.
76. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401.
77. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, Origuchi T, Ueki Y, Eguchi K (2011) Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 31:451-456.
78. Kerekes G, Soltész P, Dér H, Veres K, Szabó Z, Végvári A, Szegedi G, Shoenfeld Y, Szekanecz Z (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:705-710.
79. Keul P, Tölle M, Lucke S, von Wnuck LK, Heusch G, Schuchardt M, van der Giet M, Levkau B (2007) The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27:607-613.
80. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169-1196.
81. Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU (2014) Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 73:161-169.
82. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G (2007) Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 1108:83-91.
83. Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA (2009) Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 21:283-288.
84. Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A (2011) Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 21:916-920.
85. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL (1993) In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 90:12040-12044.
86. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701-1711.
87. Liu G, Yang K, Burns S, Shrestha S, Chi H (2010) The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 11:1047-1056.
88. Longnecker R, Miller CL (1996) Regulation of Epstein-Barr virus latency by latent membrane protein 2. Trends Microbiol 4:38-42.
89. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349.
90. Marchesi S, Lupattelli G, Lombardini R, Sensini A, Siepi D, Mannarino M, Vaudo G, Mannarino E (2005) Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis 178:345-350.
91. Marik PE (2006) Dyslipidemia in the critically ill. Crit Care Clin 22:151-159.
92. Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M (2010) Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 77:50-52.
93. Mathison JC, Ulevitch RJ (1979) The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 123:2133-2143.
94. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360.
95. McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP (2009) Inflammation impairs reverse cholesterol transport in vivo. Circulation 119:1135-1145.
96. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N (2014) Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204345 (in press)
97. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitzgerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH (2011) High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 70:1619-1624.
98. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 147:1031-1039.
99. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, Van Voorhees A, Gelfand JM (2012) Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 224:218-221.
100. Messedi M, Jamoussi K, Frigui M, Laporte F, Turki M, Chaabouni K, Mnif E, Jaloulli M, Kaddour N, Bahloul Z, Ayedi F (2011) Atherogenic lipid profile in Behcet’s disease: evidence of alteration of HDL subclasses. Arch Med Res 42:211-218.
101. Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16-19.
102. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J (2007) Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 27:893-900.
103. Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila O (2005) CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 140:360-367.
104. Musabak U, Baylan O, Cetin T, Yesilova Z, Sengul A, Saglam K, Inal A, Kocar IH (2005) Lipid profile and anticardiolipin antibodies in Behcet’s disease. Arch Med Res 36:387-392.
105. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:482-487.
106. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8:222-232.
107. Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell’Italia LJ, Moreland LW, O’Dell JR, Paulus HE, Curtis JR (2013) Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 65:1430-1438.
108. Newburger JW, Burns JC, Beiser AS, Loscalzo J (1991) Altered lipid profile after Kawasaki syndrome. Circulation 84:625-631.
109. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA (2007) FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115:501-508.
110. Norata GD, Catapano AL (2012) HDL and adaptive immunity: a tale of lipid rafts. Atherosclerosis 225:34-35.
111. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL (2005) High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111:2805-2811.
112. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28:925-931.
113. Norata GD, Pirillo A, Ammirati E, Catapano AL (2012) Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220:11-21.
114. O’Connell BJ, Denis M, Genest J (2004) Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation 110:2881-2888.
115. O’Neill SG, Giles I, Lambrianides A, Manson J, D’Cruz D, Schrieber L, March LM, Latchman DS, Isenberg DA, Rahman A (2010) Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 62:845-854.
116. Orem A, Yandi YE, Vanizor B, Cimsit G, Uydu HA, Malkoc M (2002) The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behcet’s disease. Clin Biochem 35:217-224.
117. Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L (2009) Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn’s disease. Inflamm Bowel Dis 15:1476-1484.
118. Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT (2007) Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 66:958-961.
119. Phillips MC (2013) New insights into the determination of HDL structure by apolipoproteins: thematic review series: high density lipoprotein structure, function, and metabolism. J Lipid Res 54:2034-2048.
120. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME (2010) A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 29:947-955.
121. Prosser HC, Ng MK, Bursill CA (2012) The role of cholesterol efflux in mechanisms of endothelial protection by HDL. Curr Opin Lipidol 23:182-189.
122. Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT (2013) HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 72:560-565.
123. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, CANTOS Pilot Investigative Group (2012) Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739-2748.
124. Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8:753-763.
125. Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, Zambon S, Basato S, Zanoni S, Filosa T, Pilon F, Manzato E (2009) Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther 29:298-307.
126. Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL (2014) Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 73(3):609-615. doi:10.1136/annrheumdis-2012-202914.
127. Sala F, Cutuli L, Grigore L, Pirillo A, Chiesa G, Catapano AL, Norata GD (2013) Prevalence of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. Int J Cardiol 168:2886-2889.
128. Salazar A, Mana J, Pinto X, Argimon JM, Hurtado I, Pujol R (2002) Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta 320:59-64.
129. Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P, Trentacosti A, Massenti MF, Savettieri G, Bono A (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19.
130. Sappati Biyyani RS, Putka BS, Mullen KD (2010) Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol 4:478-482.
131. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED (2007) Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 56:631-638.
132. Scanu AM, Edelstein C (2008) HDL: bridging past and present with a look at the future. FASEB J 22:4044-4054.
133. Sethi A, Parmar HS, Kumar A (2011) The effect of aspirin on atherogenic diet-induced diabetes mellitus. Basic Clin Pharmacol Toxicol 108:371-377.
134. Shah S, Casas JP, Drenos F, Whittaker J, Deanfield J, Swerdlow DI, Holmes MV, Kivimaki M, Langenberg C, Wareham N, Gertow K, Sennblad B, Strawbridge RJ, Baldassarre D, Veglia F, Tremoli E, Gigante B, de Faire U, Kumari M, Talmud PJ, Hamsten A, Humphries SE, Hingorani AD (2013) Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. Circ Cardiovasc Genet 6:63-72.
135. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL (2005) Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 280:32578-32585.
136. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347.
137. Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, Chaddha M, Kurundkar AR, Datta G (2010) Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 298:C1538-C1548.
138. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 14:R141.
139. Tardif JC, L’allier PL, Ibrahim R, Grégoire JC, Nozza A, Cossette M, Kouz S, Lavoie MA, Paquin J, Brotz TM, Taub R, Pressacco J (2010) Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 3:298-307.
140. Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM, FTY720 Study Group (2006) Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82:1689-1697.
141. Teixeira PC, Cutler P, Vuilleumier N (2012) Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol 2012:868251. doi:10.1155/2012/868251.
142. Terasaka N, Wang N, Yvan-Charvet L, Tall AR (2007) High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 104:15093-15098.
143. Thuahnai ST, Lund-Katz S, Anantharamaiah GM, Williams DL, Phillips MC (2003) A quantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipidassociated apolipoproteins. J Lipid Res 44:1132-1142.
144. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K (2002) Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 115:2603-2611.
145. Troitzsch P, Paulista Markus MR, Dorr M, Felix SB, Junger M, Schminke U, Schmidt CO, Volzke H, Baumeister SE, Arnold A (2012) Psoriasis is associated with increased intimamedia thickness-the Study of Health in Pomerania (SHIP). Atherosclerosis 225:486-490.
146. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758-2767
147. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, Kastelein JJ, Stroes ES, de Groot E, Hommes DW (2007) Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res 48:2640-2646.
148. Viñals M, Bermúdez I, Llaverias G, Alegret M, Sanchez RM, Vázquez-Carrera M, Laguna JC (2005) Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 66:141-149.
149. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572-580.
150. Vuilleumier N, Dayer JM, von Eckardstein A, Roux-Lombard P (2013) Pro-or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Med Wkly 143:w13781.
151. Vuilleumier N, Montecucco F, Hartley O (2014) Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 6(5):314-326. doi:10.4330/wjc.v6.i5.314.
152. Wang Y, Zhu X, Wu G, Shen L, Chen B (2008) Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J Lipid Res 49:1640-1645.
153. Wang SH, Yuan SG, Peng DQ, Zhao SP (2012) HDL and ApoA-I inhibit antigen presentationmediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis 225:105-114.
154. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST (2012) Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64:1828-1837.
155. Weigert A, Weis N, Brune B (2009) Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology 214:748-760.
156. Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365-376.
157. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG (2009) Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 29:843-849.
158. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, Bhat S, Gibbs DP Jr, Thomas MJ, Sorci-Thomas MG (2010) Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/-mice. J Biol Chem 285:36158-36169.
159. Williams HR, Willsmore JD, Cox IJ, Walker DG, Cobbold JF, Taylor-Robinson SD, Orchard TR (2012) Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 57:2157-2165.
160. Yatomi Y (2008) Plasma sphingosine 1-phosphate metabolism and analysis. Biochim Biophys Acta 1780:606-611.
161. Young D, Peterson C, Basch C, Halladay SC (1995) Effects of naproxen and nabumetone on serum cholesterol levels in patients with osteoarthritis. Clin Ther 17:231-240.
162. Yu Y, Sheth N, Krishnamoorthy P, Saboury B, Raper A, Baer A, Ochotony R, Doveikis J, Derohannessian S, Voorhees AS, Torigian DA, Alavi A, Gelfand JM, Mehta NN (2012) Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2:285-292.
163. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW (2001) High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7:853-857.
164. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR (2010a) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328:1689-1693.
165. Yvan-Charvet L, Wang N, Tall AR (2010b) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 30:139-143.
166. Zapolska-Downar D, Naruszewicz M, Zapolski-Downar A, Markiewski M, Bukowska H, Millo B (2000) Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers. Eur J Clin Invest 30:1002-1010